| Literature DB >> 33948270 |
Latrice Rollins1, Nicole Llewellyn2, Manzi Ngaiza1, Eric Nehl2, Dorothy R Carter3, Jeff M Sands2.
Abstract
INTRODUCTION: The Clinical and Translational Science Awards (CTSA) program of the National Center for Advancing Translational Sciences (NCATS) seeks to improve population health by accelerating the translation of scientific discoveries in the laboratory and clinic into practices for the community. CTSAs achieve this goal, in part, through their pilot project programs that fund promising early career investigators and innovative early-stage research projects across the translational research spectrum. However, there have been few reports on individual pilot projects and their impacts on the investigators who receive them and no studies on the long-term impact and outcomes of pilot projects.Entities:
Keywords: CTSA program; Pilot project program; case studies; evaluation; research payback
Year: 2020 PMID: 33948270 PMCID: PMC8057435 DOI: 10.1017/cts.2020.542
Source DB: PubMed Journal: J Clin Transl Sci ISSN: 2059-8661
Selected Case Characteristics
| Number of Cases ( | Overall ( | |
|---|---|---|
| Timeframe (Start Date) | ||
| 2007–2009 | 4 | 56 |
| 2010–2012 | 3 | 55 |
| 2013–2015 | 9 | 60 |
| Amount of Funding | ||
| $24,500–$25,000 | 4 | 11 |
| $27,500–$30,000 | 4 | 73 |
| $50,000 | 5 | 28 |
| $70,000–$75,000 | 2 | 7 |
| $200,000 | 1 | 21 |
| Rank of Principal Investigator | ||
| Instructor | 1 | 6 |
| Assistant Professor | 4 | 84 |
| Associate Professor | 5 | 53 |
| Professor | 1 | 36 |
| Multi-Institutional (Yes) | 6 | 60 |
| Translation Phase | ||
| T1-Translation to Humans | 7 | 130 |
| T2-Translation to Patients | 1 | 35 |
| T3-Translation to Practice | 2 | 14 |
| T4-Translation to Community | 1 | 4 |
Interview guide for Georgia CTSA pilot project investigators
| Opening Questions - Overall Project Implementation | What were the aims/goals of your project? |
| What was the biggest win/success in implementation of those aims/goals? | |
| Were there any concerns, challenges, or struggles that you experienced in implementing this project? If, so please tell us more about them? | |
| How did you respond to the concerns, challenges, or struggles? | |
| How did program leadership (i.e., NIH, Georgia CTSA staff) support or respond to this issue? | |
| Knowledge Production | Did you file any patents as a result of this project? Please describe them. |
| Did you share any information about this project? Please describe your dissemination efforts (i.e., journal, newsletter, factsheet, radio, presentations). | |
| Did you or any members of your research team receive any awards associated with this project? Please describe them. | |
| Research targeting, capacity building and absorption | During the course of completing this project, did you receive any additional degrees, or obtain faculty appointment or promotion? |
| Do you attribute any degrees or faculty appointment/promotion to this project? | |
| Did you train or mentor anyone to assist with this project? Please describe them. | |
| Did you submit additional grants to support/continue this work? Please describe those submitted and funded. | |
| Informing policy and product development | Describe any translation of the research findings into products, policies and/or practice. |
| Have any research outcomes/products been adopted by practitioners or public? Please describe | |
| Broader economic benefits | Describe any employment and profits that resulted from this project, if any (i.e., manufacture and sale of drugs and devices, training materials). |
| Describe any cost savings related to the research/adoption of your project. | |
| Describe any estimates of economic burden of the target health issue and the potential role your research played in reducing it. | |
| Health benefits | Describe your perspectives regarding any increased health outcomes as a result of your research. |
| Please describe the overall impact of your pilot project research from your perspective. | |
| Are there any additional resources or support mechanisms that you think would be useful in enhancing the pilot projects’ impact? | |
| Closing Question- Targeted Evaluation Foci | What other noteworthy components of pilot projects you believe are critical to understand and evaluate? |
Analysis of pilot project outcomes of 16 selected projects by payback domains
| Payback Domains | Pilot Project Outcomes ( |
|---|---|
| Knowledge Production |
54 publications with a total of 1125 academic citations and reference in 35 news stories, 8 blog posts, and 150 tweets |
|
Published in 37 different journals | |
|
4 patents filed; 3 patents issued | |
|
20 scientific presentations | |
|
|
1.66 (over 1 is considered above average) |
| Research Targeting, Capacity Building, and Absorption |
4 of 11 investigators were promoted |
|
Approximately 30 graduate students and fellows were mentored | |
| Informing Policy and Product Development |
Helped develop guidelines for handling staph infections in children |
|
Radiography machines installed in clinic | |
|
Working with over 40 medical centers globally | |
|
Pilot research publications have been referenced in 4 patents and 1 policy document | |
| Health and Health Sector Benefits |
Improved stroke survivor physical function while reducing caregiver negative outcomes |
|
Improved outcomes in heart failure and diabetes | |
|
Examined community-associated methicillin resistant Staphylococcus aureus (CA-MRSA) carriage and infections and determine risk factors associated specifically with MRSA USA300 | |
|
Staphylococcus aureus colonization rates in pediatric health care workers from different types of outpatient settings were determined | |
|
Demonstrated diabetic neuropathy could be reversed by local transplantation of Endothelial progenitor cells | |
|
Improved and novel systems that can be valuable for cell therapy (e.g., for cardiovascular diseases, diabetes), regenerative medicine, and drug discovery including opening a new era of nonhuman primate modeling of human diseases | |
|
Developed innovations in medical imaging | |
|
Developed advances in limb replacement strategies | |
|
Comprehensive delineation of genetic, functional and phenotypic aspects of GRIN2B encephalopathy | |
| Broader Economic Benefits |
Unquantified costs savings due to reduced patient and disease burden |
|
Additional savings due to improved healthcare procedures |
Distribution of publications within Web of Science Research Areas (WoSRAs) and associated Category Normalized Citation Impact (CNCI) scores
| WoSRA | # of Publications | Average Category |
|---|---|---|
| CARDIAC & CARDIOVASCULAR SYSTEMS | 13 | 1.46 |
| PERIPHERAL VASCULAR DISEASE | 7 | 1.70 |
| GENETICS & HEREDITY | 6 | 3.58 |
| RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | 6 | 0.62 |
| CELL & TISSUE ENGINEERING | 5 | 0.74 |
| BIOCHEMISTRY & MOLECULAR BIOLOGY | 4 | 1.53 |
| ENGINEERING, BIOMEDICAL | 4 | 1.40 |
| SURGERY | 4 | 0.84 |
| CELL BIOLOGY | 3 | 0.77 |
| MATERIALS SCIENCE, BIOMATERIALS | 3 | 1.75 |
| PHARMACOLOGY & PHARMACY | 3 | 2.95 |
| BIOCHEMICAL RESEARCH METHODS | 2 | 2.91 |
| ENDOCRINOLOGY & METABOLISM | 2 | 0.27 |
| INFECTIOUS DISEASES | 2 | 2.45 |
| NEUROSCIENCES | 2 | 2.17 |
| PHYSIOLOGY | 2 | 0.62 |
| REHABILITATION | 2 | 0.98 |
| BIOTECHNOLOGY & APPLIED MICROBIOLOGY | 1 | 1.06 |
| EMERGENCY MEDICINE | 1 | 1.65 |
| HEMATOLOGY | 1 | 3.18 |
| NURSING | 1 | 3.04 |
| PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | 1 | 0.25 |
| TRANSPLANTATION | 1 | 1.06 |
Bibliometric data stratified by time since pilot was awarded
| Years pilots were awarded | # of pilot grants | # of publications | # of citations | Citations per | CNCI | JIF | JIF Percentile |
|---|---|---|---|---|---|---|---|
| Mean | Mean | ||||||
| CTSA Grant Years 1–3: 2007–2010 | 4 | 15 | 410 | 29 | 1.30 | 8.77 | 75.94 |
| CTSA Grant Years 4–6: 2010–2013 | 5 | 11 | 108 | 11 | 0.91 | 4.09 | 56.02 |
| CTSA Grant Years 7–9: 2013–2015 | 7 | 28 | 607 | 22 | 2.03 | 5.58 | 79.17 |
| All Years | 16 | 54 | 1125 | 21.63 | 1.66 | 6.53 | 75.28 |
| (0–115) | (0–4.91) | (1.45–23.05) | (16.28–99.06) |
CNCI, category normalized citation impact; JIF, journal impact factor
values are rounded to the nearest whole number
values are representative of available publications
Note: Citation analyses based on 52 publications indexed in InCites.